Limitations and Unmet Needs of Existing Treatments

After allogeneic hematopoietic stem cell transplantation (allo-HSCT), patients experience severe immune deficiency, making them susceptible to various life-threatening viral infections. Conventional antiviral treatments, such as ganciclovir or foscarnet, achieve only about 60-80% response rates, leaving more than one in five patients failing treatment. Furthermore, these drugs are associated with significant side effects, including nephrotoxicity and bone marrow suppression, often leading to treatment discontinuation. Therefore, there is an urgent need for an immune reconstitution therapy that minimizes side effects and eliminates drug-resistant viruses.

Technological Innovation of CD45RA-Depleted DLI

This clinical study introduces a technology that targets and removes the CD45RA molecule, a marker of naive T cells, to overcome the side effects of donor lymphocyte infusion (DLI). Using the CliniMACS automated cell separation system from Miltenyi Biotec, the study precisely filters out CD45RA-positive cells that cause graft-versus-host disease (GVHD). Meanwhile, memory T cells, which directly combat viruses, are preserved and infused into the patient, maximizing therapeutic efficacy. This is an innovative approach that goes beyond simple viral suppression and safely restores the patient's immune function.

Clinical Design and Safety Verification at Ruijin Hospital

This Phase 1/2 clinical trial, led by Ruijin Hospital in China, will enroll a total of 30 patients to simultaneously evaluate safety and efficacy. The research team will assess the overall response rate based on quantitative PCR (qPCR) results and clinical symptom relief at 90 days post-infusion. As a secondary endpoint, the incidence of grade 3-4 acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) will be monitored to establish the safety limits of the cell therapy. This study is expected to further refine the clinical safety criteria for memory T cell-based immune therapy platforms.

Potential to Disrupt the Market for Refractory Infections

The market for post-transplant viral infection treatments has significant unmet needs and is a key target for multinational pharmaceutical companies. For example, Takeda's Livtencity (maribavir) for refractory CMV infections is projected to generate peak annual sales of $700-800 million. If this CD45RA-depleted lymphocyte infusion is successfully commercialized, it could become a powerful cell therapy alternative in the prophylactic and therapeutic market currently dominated by Takeda's maribavir and Merck's Prevymis (letermovir). Its ability to cure even multi-drug resistant viruses with a single administration gives it significant commercial value upon market entry.

Prospects for Next-Generation Cell Therapy Paradigms

This trial serves as a testbed to demonstrate how individualized, custom-engineered cell technologies can be rapidly and safely applied in clinical settings. It demonstrates a shift in the paradigm of post-transplant complication management, moving away from traditional antiviral chemotherapy towards rebuilding the patient's immune ecosystem. If this technology is successfully proven, it will provide new treatment opportunities for a wide range of patients with refractory infections after not only hematopoietic stem cell transplantation but also solid organ transplantation. Furthermore, it is expected to strengthen the technological competitiveness of the global cell therapy market, particularly in the Asia-Pacific (APAC) region.